Triastek,
Triastek is developing innovative 3D printed pharmaceuticals that revolutionize oral drug delivery by enhancing formulation efficiency and optimizing drug release profiles.
- CEO / Founder
- Senping Cheng
- Team Size
- 11-50
- Stage
- Active
- Total Funding
- $122.4M
- Latest Round
- Pre-Series C
- Key Investors
- Tasly Holding Group, Morningside Venture Capital, Volcanics Venture, Dalton Venture, Yunqi Partners, Xiaodong Zheng, Matrix Partners China, CPE, Shanghai Sci-Tech Innovation Center Capital, Triwise Capital, Goldmine Multi-family Office
Technology & Products
Key Products
3D printed pharmaceuticals, Melt Extrusion Deposition (MED) process, three IND (Investigational New Drug) applications filed.
Technological Advantage
Enables continuous, customizable tablet fabrication improving drug absorption and stability while significantly reducing development timelines.
Differentiation
Value Proposition
Enhancing formulation development efficiency and optimizing drug release profiles through proprietary 3D printing technology.
How They Differentiate
First mover in continuous 3D printed drug manufacturing with unique tablet geometries and a strong focus on digital drug development.
Market & Competition
Target Customers
Pharmaceutical companies and patients seeking advanced drug delivery solutions
Industry Verticals
["Pharmaceuticals","Healthcare","Drug Development","Manufacturing"]
Competitors
Aprecia Pharmaceuticals; FabRx
Growth & Milestones
Growth Metrics
Advanced multiple products into clinical stages with several FDA IND clearances
Major Milestones
["FDA IND clearance for its 3D printed product T20G","Successful IND clearances for T19, T21, and T22","Collaboration and platform technology license agreement with BioNTech for oral RNA therapeutics","Completion of $20.4 million funding round"]
Notable Customers
BioNTech (research partnership for 3D-printed oral RNA therapeutics), Boehringer Ingelheim GmbH (partnership for novel drug development).